Demodex density increases after adalimumab therapy in ankylosing spondylitis: a pilot study

Demodex infestation and density changes remain one of the main challenges in some clinical settings. Tumour necrosis factor-α (TNF-α) inhibitors have been recommended as a first-line treatment for ankylosing spondylitis (AS). However, there have been no studies investigating the impact of TNF-α inhi...

Full description

Saved in:
Bibliographic Details
Published inParasitology Vol. 149; no. 7; pp. 940 - 943
Main Authors Li, Xuegang, Lam, Nelson Siu Kei, Yang, Li, Liang, Anqi, Long, Xin Xin, Guo, Junli, Zhong, Shuping
Format Journal Article
LanguageEnglish
Published Cambridge, UK Cambridge University Press 01.06.2022
Subjects
Ankylosing spondylitis
Arthritis
C-reactive protein
Demodex
Density
Monoclonal antibodies
TNF inhibitors
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Tumors
Demodex
tumour necrosis factor-α
Adalimumab
ankylosing spondylitis
Online AccessGet full text

Cover

More Information
Summary:Demodex infestation and density changes remain one of the main challenges in some clinical settings. Tumour necrosis factor-α (TNF-α) inhibitors have been recommended as a first-line treatment for ankylosing spondylitis (AS). However, there have been no studies investigating the impact of TNF-α inhibitor adalimumab on changes in the Demodex density in patients with AS. The aim of this study was to investigate Demodex density changes before and after adalimumab treatment and analyse the relationship between the Demodex density and clinical characteristics in AS. It was found that the Demodex density was positively correlated with age and C-reactive protein levels and the number of Demodex mites could increase after adalimumab treatment in AS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0031-1820
1469-8161
DOI:10.1017/S0031182022000348